Researchers at the Salk Institute have used CRISPR to uncover hidden microproteins that control fat cell growth and lipid storage, identifying one confirmed target, Adipocyte-smORF-1183. This breakthrough could lead to more effective obesity treatments, surpassing the limitations of current drugs like GLP-1.
